Abilify aripiprazole

Abilify is a well-known antipsychotic medication containing the active ingredient aripiprazole. It was originally discovered and developed by the Japanese pharmaceutical company Otsuka Pharmaceutical. Upon its market entry, Otsuka collaborated with Bristol-Myers Squibb for global commercialization, though the brand remains an essential part of Otsuka's portfolio.

Manufacturing for Abilify occurs across various global sites to meet international demand, including facilities in Japan, the United States, and Europe (such as Ireland). The brand's ownership is firmly rooted in Japan, where Otsuka Pharmaceutical Co., Ltd. oversees its development and licensing as part of its broader healthcare mission.